|Bid||26.18 x 0|
|Ask||26.19 x 0|
|Day's Range||24.72 - 26.63|
|52 Week Range||11.20 - 26.63|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The trade group representing U.S. drugmakers on Friday said it has a filed a lawsuit to stop California from implementing a law aimed at reining in prescription drug prices. The Pharmaceutical Research and Manufacturers of America (PhRMA), in a statement, said it filed litigation in the U.S. District Court for the Eastern District of California challenging a state law requiring drug manufacturers to give notice and a justification for price increases of certain drugs. The law, Senate Bill 17, was signed by California Governor Jerry Brown in October and is set to take effect Jan. 1, 2019.
Activist investor Bill Ackman and his estranged former collaborator in a 2014 hostile takeover bid for Botox-maker Allergan Inc. will likely face a jury trial next month over claims they engaged in insider ...
The Vetr crowd on Thursday upgraded its rating on Valeant Pharmaceuticals International, Inc. (NYSE: VRX ), from 4 stars (Buy), issued two days ago, to 5 stars. Crowd sentiment at the time of the upgrade ...
Canada's main stock index rose on Thursday, boosted by gains for financial and energy stocks and bounceback rises for discount store chain Dollarama Inc , commerce software company Shopify and Valeant ...
Two years ago, Valeant Pharmaceuticals International Inc. shares plunged off a cliff. Now, some investors are starting to pick them up and dust them off.
Billionaire investor Bill Ackman’s audacious partnership with Valeant Pharmaceuticals International Inc. to make a hostile bid for drug company Allergan Inc. in 2014 brought him a windfall of more than ...
Jim Simons, the founder of one of the world's most successful hedge funds, is splashing out on controversial healthcare stock Valeant Pharmaceuticals (NYSE:VRX). However, this fund guru is displaying a more cautious attitude towards Opko Health (NASDAQ:OPK). Will these moves take his $85 billion fund to new heights?
Valeant Pharmaceuticals sees its Relative Strength Rating move into the elite 90-plus level.
Valeant Pharmaceuticals International Inc., returned to the bond market to start refinancing the more than $4 billion of junk debt that the drugmaker has coming due starting in just over two years. Valeant is weighed down by a $27 billion debt load that it accumulated to fund acquisitions. Valeant has cut its debt burden from around $30 billion at the start of the year through these measures.
Valeant Pharmaceuticals (NYSE:VRX) management boiled down its position to BTIG analyst Tim Chiang, where the discussion gravitated on the standing of the company's three leading segments: Bausch + Lamb/International, Branded Rx, and U.S. Diversified products. The biotech giant is not out of the woods, says Chiang after talking over the company's bigger picture with the VRX team. However, does some growth potential remain for this comeback kid of the Street just yet?
Valeant Pharmaceuticals International Inc. said Monday it is once again borrowing in the bond market to repay debt. The Laval, Quebec-based company said it is planning to offer $1 billion of senior notes ...
A Wall Street high-roller like Ken Griffin did not make it among the big leagues a.k.a. on Forbes' rich list, without understanding the value in capitalizing on a bull market. Was it a smart third quarter move for Citadel's CEO and founder to up his stakes significantly in biotech movers and shakers Valeant (NYSE:VRX) and Teva (NYSE:TEVA)?
As we enter the last month of the year, here is a look at some pharma and biotech companies including Amgen (AMGN) that await a decision from the FDA for label expansions or new drugs.
Valeant Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
Valeant Pharmaceuticals, which has been Exhibit A of corporate turbulence since 2015, is trying to get back to being a normal drug company. But it faces a steep climb to good health.
EyeGate (EYEG) reported Q3 financial results and provided a business update. There continue to be no significant surprises in the financials. Operating expenses continue to trend higher on progression of several development programs including EDP-437, which is in clinical trials for indications related to anterior uveitis and post-cataract surgery.
When quant billionaire David Shaw trades, the world listens. One of the most successful hedge funds of all time, Shaw has now made a number of intriguing moves in the last quarter including snapping up Valeant Pharmaceuticals International, Inc. (NYSE:VRX) and MannKind Corporation (NASDAQ:MNKD). Take a closer look at the fund’s top Q3 moves.